<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01938430</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-337-0123</org_study_id>
    <nct_id>NCT01938430</nct_id>
  </id_info>
  <brief_title>Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant</brief_title>
  <official_title>A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected With Chronic HCV Who Have Advanced Liver Disease or Are Post-Liver Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) plus
      ribavirin (RBV) in participants with advanced liver disease or posttransplant and chronic
      genotype 1 or 4 hepatitis C virus (HCV) infection.

        -  Cohort A: decompensated cirrhosis (advanced liver disease), no prior liver transplant;

        -  Cohort B: post-liver transplant, with or without cirrhosis;

        -  Group assignment within cohorts is based on severity of liver impairment at screening
           (Child-Pugh-Turcotte (CPT) score for participants with cirrhosis; fibrosis; or presence
           of disease for fibrosing cholestatic hepatitis (FCH) groups)

        -  Randomization is 1:1 within groups to 12 or 24 weeks of LDV/SOF+RBV treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</measure>
    <time_frame>Posttreatment Week 12</time_frame>
    <description>SVR12 was defined as HCV RNA &lt; the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With SVR 2 Weeks After Discontinuation of Therapy (SVR2)</measure>
    <time_frame>Posttreatment Week 2</time_frame>
    <description>SVR2 was defined as HCV RNA &lt; LLOQ at 2 weeks after stopping study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With SVR 4 Weeks After Discontinuation of Therapy (SVR4)</measure>
    <time_frame>Posttreatment Week 4</time_frame>
    <description>SVR4 was defined as HCV RNA &lt; LLOQ at 4 weeks after stopping study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With SVR 8 Weeks After Discontinuation of Therapy (SVR8)</measure>
    <time_frame>Posttreatment Week 8</time_frame>
    <description>SVR8 was defined as HCV RNA &lt; LLOQ at 8 weeks after stopping study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With SVR 24 Weeks After Discontinuation of Therapy (SVR24)</measure>
    <time_frame>Posttreatment Week 24</time_frame>
    <description>SVR24 was defined as HCV RNA &lt; LLOQ at 24 weeks after stopping study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Failure</measure>
    <time_frame>Up to Posttreatment Week 24</time_frame>
    <description>Virologic failure was defined as:
On-treatment virologic failure:
Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ on 2 consecutive measurements while on treatment), or
Rebound (confirmed &gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment)
Virologic relapse:
Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA &lt; LLOQ at last on-treatment visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Posttransplant Virologic Response (pTVR) at Posttransplant Week 12</measure>
    <time_frame>Posttransplant Week 12</time_frame>
    <description>pTVR was defined as HCV RNA &lt; LLOQ at Week 12 after transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 1</measure>
    <time_frame>Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 2</measure>
    <time_frame>Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 4</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 6</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 8</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 16</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 20</measure>
    <time_frame>Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV RNA and Change From Baseline at Week 1</measure>
    <time_frame>Baseline; Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV RNA and Change From Baseline at Week 2</measure>
    <time_frame>Baseline; Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV RNA and Change From Baseline at Week 4</measure>
    <time_frame>Baseline; Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV RNA and Change From Baseline at Week 6</measure>
    <time_frame>Baseline; Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV RNA and Change From Baseline at Week 8</measure>
    <time_frame>Baseline; Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV RNA and Change From Baseline at Week 12</measure>
    <time_frame>Baseline; Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Decrease, No Change, or Increase Between Baseline and Posttreatment Week 4 in MELD Score</measure>
    <time_frame>Baseline to Posttreatment Week 4</time_frame>
    <description>Model for End-Stage Liver Disease (MELD) scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40; higher scores/increased scores indicate greater severity of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Decrease, No Change, or Increase Between Baseline and Posttreatment Week 4 in CPT Score</measure>
    <time_frame>Baseline to Posttreatment Week 4</time_frame>
    <description>CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15 (maximum score for entry into the study was 12); higher scores/increased scores indicate greater severity of disease. Groups are arranged by cohort, then by duration of treatment, then by CPT class at baseline.</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">339</enrollment>
  <condition>Chronic HCV Infection</condition>
  <arm_group>
    <arm_group_label>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF (90/400 mg) plus RBV (weight-based: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF (90/400 mg) plus RBV (weight-based: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF (90/400 mg) plus RBV (weight-based: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF (90/400 mg) plus RBV (weight-based: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B, Group 7 (12 wk): FCH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF (90/400 mg) plus RBV (weight-based: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with FCH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B, Group 7 (24 wk): FCH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF (90/400 mg) plus RBV (weight-based: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDV/SOF</intervention_name>
    <description>LDV/SOF FDC tablet administered orally once daily</description>
    <arm_group_label>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</arm_group_label>
    <arm_group_label>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</arm_group_label>
    <arm_group_label>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</arm_group_label>
    <arm_group_label>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</arm_group_label>
    <arm_group_label>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</arm_group_label>
    <arm_group_label>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</arm_group_label>
    <arm_group_label>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</arm_group_label>
    <arm_group_label>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</arm_group_label>
    <arm_group_label>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</arm_group_label>
    <arm_group_label>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</arm_group_label>
    <arm_group_label>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</arm_group_label>
    <arm_group_label>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</arm_group_label>
    <arm_group_label>Cohort B, Group 7 (12 wk): FCH</arm_group_label>
    <arm_group_label>Cohort B, Group 7 (24 wk): FCH</arm_group_label>
    <other_name>Harvoni®</other_name>
    <other_name>GS-5885/GS-7977</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBV</intervention_name>
    <description>RBV tablets administered orally in a divided daily dose</description>
    <arm_group_label>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</arm_group_label>
    <arm_group_label>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</arm_group_label>
    <arm_group_label>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</arm_group_label>
    <arm_group_label>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</arm_group_label>
    <arm_group_label>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</arm_group_label>
    <arm_group_label>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</arm_group_label>
    <arm_group_label>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</arm_group_label>
    <arm_group_label>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</arm_group_label>
    <arm_group_label>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</arm_group_label>
    <arm_group_label>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</arm_group_label>
    <arm_group_label>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</arm_group_label>
    <arm_group_label>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</arm_group_label>
    <arm_group_label>Cohort B, Group 7 (12 wk): FCH</arm_group_label>
    <arm_group_label>Cohort B, Group 7 (24 wk): FCH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide written informed consent

          -  Chronic genotype 1 or 4 HCV infection

          -  Normal ECG

          -  Negative serum pregnancy test for female subjects

          -  Male subjects and female subjects of childbearing potential must agree to use
             contraception

          -  Able to comply with the dosing instructions for study drug and able to complete the
             study schedule of assessments, including all required post treatment visits

        Exclusion Criteria:

          -  Serious or active medical or psychiatric illness

          -  HIV or hepatitis B viral (HBV) infection

          -  Stomach disorder that could interfere with the absorption of the study drug

          -  Treated with an anti-HCV medication in the last 30 days

          -  Any prior exposure to an HCV nonstructural protein (NS)5a-specific inhibitor

          -  Use of human granulocyte-macrophage colony-stimulating factor (GM-CSF), epoetin alfa
             or other therapeutic hematopoietic agents within 2 weeks of screening

          -  History of clinically significant medical condition associated with other chronic
             liver disease

          -  Active spontaneous bacterial peritonitis at screening

          -  Females who are breastfeeding

          -  Infection requiring systemic antibiotics

          -  Participated in a clinical study with an investigational drug or biologic within the
             last 30 days

          -  Active or history (last 6 months) of drug or alcohol abuse

          -  History of organ transplant other than liver or kidney
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shampa De-Oertel, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2013</study_first_submitted>
  <study_first_submitted_qc>September 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <results_first_submitted>March 16, 2016</results_first_submitted>
  <results_first_submitted_qc>March 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 15, 2016</results_first_posted>
  <disposition_first_submitted>November 4, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>November 4, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 1, 2015</disposition_first_posted>
  <last_update_submitted>March 16, 2016</last_update_submitted>
  <last_update_submitted_qc>March 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study sites in the United States. The first participant was screened on 06 September 2013. The last study visit occurred on 25 March 2015.</recruitment_details>
      <pre_assignment_details>Cohort A: decompensated cirrhosis (advanced liver disease), no prior liver transplant;
Cohort B: post-liver transplant, with or without cirrhosis;
Group assignment within cohorts was based on severity of liver impairment at screening (or presence of disease for FCH groups);
Randomization was 1:1 within groups to 12 or 24 weeks of treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
          <description>Ledipasvir/sofosbuvir (Harvoni®; LDV/SOF) (90/400 mg) fixed-dose combination (FDC) tablet once daily plus ribavirin (RBV) tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with Child-Pugh-Turcotte (CPT) Class B (CPT score 7-9).
CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15 (maximum score for study was 12); higher scores indicate greater severity of disease.</description>
        </group>
        <group group_id="P2">
          <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
        </group>
        <group group_id="P3">
          <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
        </group>
        <group group_id="P4">
          <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
        </group>
        <group group_id="P5">
          <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3
F0: no fibrosis; F1: portal fibrosis without septa; F2: portal fibrosis with rare septa, F3: numerous septa without cirrhosis; F4: cirrhosis</description>
        </group>
        <group group_id="P6">
          <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
        </group>
        <group group_id="P7">
          <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
        </group>
        <group group_id="P8">
          <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
        </group>
        <group group_id="P9">
          <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
        </group>
        <group group_id="P10">
          <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
        </group>
        <group group_id="P11">
          <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
        </group>
        <group group_id="P12">
          <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
        </group>
        <group group_id="P13">
          <title>Cohort B, Group 7 (12 wk): FCH</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
        </group>
        <group group_id="P14">
          <title>Cohort B, Group 7 (24 wk): FCH</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="55"/>
                <participants group_id="P6" count="56"/>
                <participants group_id="P7" count="26"/>
                <participants group_id="P8" count="25"/>
                <participants group_id="P9" count="26"/>
                <participants group_id="P10" count="26"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="4"/>
                <participants group_id="P13" count="4"/>
                <participants group_id="P14" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="55"/>
                <participants group_id="P6" count="55"/>
                <participants group_id="P7" count="24"/>
                <participants group_id="P8" count="24"/>
                <participants group_id="P9" count="22"/>
                <participants group_id="P10" count="23"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="4"/>
                <participants group_id="P14" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's Discretion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set: participants who were enrolled and received at least one dose of study drug</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
        </group>
        <group group_id="B2">
          <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
        </group>
        <group group_id="B3">
          <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
        </group>
        <group group_id="B4">
          <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
        </group>
        <group group_id="B5">
          <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
        </group>
        <group group_id="B6">
          <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
        </group>
        <group group_id="B7">
          <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
        </group>
        <group group_id="B8">
          <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
        </group>
        <group group_id="B9">
          <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
        </group>
        <group group_id="B10">
          <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
        </group>
        <group group_id="B11">
          <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
        </group>
        <group group_id="B12">
          <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
        </group>
        <group group_id="B13">
          <title>Cohort B, Group 7 (12 wk): FCH</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
        </group>
        <group group_id="B14">
          <title>Cohort B, Group 7 (24 wk): FCH</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
        </group>
        <group group_id="B15">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="26"/>
            <count group_id="B5" value="55"/>
            <count group_id="B6" value="56"/>
            <count group_id="B7" value="26"/>
            <count group_id="B8" value="25"/>
            <count group_id="B9" value="26"/>
            <count group_id="B10" value="26"/>
            <count group_id="B11" value="5"/>
            <count group_id="B12" value="4"/>
            <count group_id="B13" value="4"/>
            <count group_id="B14" value="2"/>
            <count group_id="B15" value="337"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="9.1"/>
                    <measurement group_id="B2" value="58" spread="6.5"/>
                    <measurement group_id="B3" value="57" spread="6.2"/>
                    <measurement group_id="B4" value="59" spread="4.6"/>
                    <measurement group_id="B5" value="59" spread="6.6"/>
                    <measurement group_id="B6" value="58" spread="6.4"/>
                    <measurement group_id="B7" value="61" spread="6.2"/>
                    <measurement group_id="B8" value="61" spread="10.4"/>
                    <measurement group_id="B9" value="59" spread="5.8"/>
                    <measurement group_id="B10" value="61" spread="6.6"/>
                    <measurement group_id="B11" value="60" spread="3.8"/>
                    <measurement group_id="B12" value="61" spread="1.7"/>
                    <measurement group_id="B13" value="62" spread="3.2"/>
                    <measurement group_id="B14" value="58" spread="8.5"/>
                    <measurement group_id="B15" value="59" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="46"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="22"/>
                    <measurement group_id="B9" value="22"/>
                    <measurement group_id="B10" value="23"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="50"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="23"/>
                    <measurement group_id="B9" value="21"/>
                    <measurement group_id="B10" value="23"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="49"/>
                    <measurement group_id="B7" value="21"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="21"/>
                    <measurement group_id="B10" value="24"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian/Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="55"/>
                    <measurement group_id="B6" value="56"/>
                    <measurement group_id="B7" value="26"/>
                    <measurement group_id="B8" value="25"/>
                    <measurement group_id="B9" value="26"/>
                    <measurement group_id="B10" value="26"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatitis C Virus (HCV) RNA</title>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.9" spread="0.68"/>
                    <measurement group_id="B2" value="5.8" spread="0.82"/>
                    <measurement group_id="B3" value="5.6" spread="0.62"/>
                    <measurement group_id="B4" value="5.8" spread="0.71"/>
                    <measurement group_id="B5" value="6.5" spread="0.62"/>
                    <measurement group_id="B6" value="6.4" spread="0.93"/>
                    <measurement group_id="B7" value="6.2" spread="0.77"/>
                    <measurement group_id="B8" value="6.7" spread="0.34"/>
                    <measurement group_id="B9" value="6.3" spread="0.55"/>
                    <measurement group_id="B10" value="6.2" spread="0.67"/>
                    <measurement group_id="B11" value="6.4" spread="0.42"/>
                    <measurement group_id="B12" value="6.3" spread="0.37"/>
                    <measurement group_id="B13" value="6.5" spread="1.24"/>
                    <measurement group_id="B14" value="7.1" spread="0.90"/>
                    <measurement group_id="B15" value="6.2" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV RNA Category</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 800 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="9"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 800 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="46"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="25"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="17"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV Genotype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Genotype 1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="40"/>
                    <measurement group_id="B6" value="40"/>
                    <measurement group_id="B7" value="17"/>
                    <measurement group_id="B8" value="17"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="18"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 1b</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IL28b Status</title>
          <description>The CC, CT, and TT alleles are different forms of the IL28b gene.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>CC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="19"/>
                    <measurement group_id="B9" value="14"/>
                    <measurement group_id="B10" value="16"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="9"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</title>
        <description>SVR12 was defined as HCV RNA &lt; the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.</description>
        <time_frame>Posttreatment Week 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least one dose of study drug. Participants in Cohort A who received a liver transplant prior to the lower bound of the Posttreatment Week 12 visit were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O11">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O12">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O13">
            <title>Cohort B, Group 7 (12 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
          </group>
          <group group_id="O14">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</title>
          <description>SVR12 was defined as HCV RNA &lt; the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.</description>
          <population>Full Analysis Set: participants who were randomized and received at least one dose of study drug. Participants in Cohort A who received a liver transplant prior to the lower bound of the Posttreatment Week 12 visit were not included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="56"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="26"/>
                <count group_id="O10" value="26"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7"/>
                    <measurement group_id="O2" value="88.9"/>
                    <measurement group_id="O3" value="86.4"/>
                    <measurement group_id="O4" value="87.0"/>
                    <measurement group_id="O5" value="96.4"/>
                    <measurement group_id="O6" value="98.2"/>
                    <measurement group_id="O7" value="96.2"/>
                    <measurement group_id="O8" value="96.0"/>
                    <measurement group_id="O9" value="84.6"/>
                    <measurement group_id="O10" value="88.5"/>
                    <measurement group_id="O11" value="60.0"/>
                    <measurement group_id="O12" value="75.0"/>
                    <measurement group_id="O13" value="100.0"/>
                    <measurement group_id="O14" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event</title>
        <time_frame>Up to 24 weeks</time_frame>
        <population>Safety Analysis Set: participants who were randomized and received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O11">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O12">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O13">
            <title>Cohort B, Group 7 (12 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
          </group>
          <group group_id="O14">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event</title>
          <population>Safety Analysis Set: participants who were randomized and received at least one dose of study drug</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="56"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="26"/>
                <count group_id="O10" value="26"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued LDV/SOF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="6.9"/>
                    <measurement group_id="O3" value="4.3"/>
                    <measurement group_id="O4" value="7.7"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="3.6"/>
                    <measurement group_id="O7" value="3.8"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="7.7"/>
                    <measurement group_id="O10" value="11.5"/>
                    <measurement group_id="O11" value="0.0"/>
                    <measurement group_id="O12" value="0.0"/>
                    <measurement group_id="O13" value="0.0"/>
                    <measurement group_id="O14" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued Any Study Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="13.8"/>
                    <measurement group_id="O3" value="13.0"/>
                    <measurement group_id="O4" value="34.6"/>
                    <measurement group_id="O5" value="10.9"/>
                    <measurement group_id="O6" value="17.9"/>
                    <measurement group_id="O7" value="15.4"/>
                    <measurement group_id="O8" value="8.0"/>
                    <measurement group_id="O9" value="23.1"/>
                    <measurement group_id="O10" value="34.6"/>
                    <measurement group_id="O11" value="40.0"/>
                    <measurement group_id="O12" value="25.0"/>
                    <measurement group_id="O13" value="25.0"/>
                    <measurement group_id="O14" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With SVR 2 Weeks After Discontinuation of Therapy (SVR2)</title>
        <description>SVR2 was defined as HCV RNA &lt; LLOQ at 2 weeks after stopping study treatment.</description>
        <time_frame>Posttreatment Week 2</time_frame>
        <population>Full Analysis Set. Participants in Cohort A who received a liver transplant prior to the lower bound of the Posttreatment Week 2 visit were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O11">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O12">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O13">
            <title>Cohort B, Group 7 (12 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
          </group>
          <group group_id="O14">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SVR 2 Weeks After Discontinuation of Therapy (SVR2)</title>
          <description>SVR2 was defined as HCV RNA &lt; LLOQ at 2 weeks after stopping study treatment.</description>
          <population>Full Analysis Set. Participants in Cohort A who received a liver transplant prior to the lower bound of the Posttreatment Week 2 visit were not included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="56"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="26"/>
                <count group_id="O10" value="26"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7"/>
                    <measurement group_id="O2" value="92.6"/>
                    <measurement group_id="O3" value="95.5"/>
                    <measurement group_id="O4" value="95.8"/>
                    <measurement group_id="O5" value="100.0"/>
                    <measurement group_id="O6" value="98.2"/>
                    <measurement group_id="O7" value="96.2"/>
                    <measurement group_id="O8" value="100.0"/>
                    <measurement group_id="O9" value="88.5"/>
                    <measurement group_id="O10" value="92.3"/>
                    <measurement group_id="O11" value="100.0"/>
                    <measurement group_id="O12" value="75.0"/>
                    <measurement group_id="O13" value="100.0"/>
                    <measurement group_id="O14" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With SVR 4 Weeks After Discontinuation of Therapy (SVR4)</title>
        <description>SVR4 was defined as HCV RNA &lt; LLOQ at 4 weeks after stopping study treatment.</description>
        <time_frame>Posttreatment Week 4</time_frame>
        <population>Full Analysis Set. Participants in Cohort A who received a liver transplant prior to the lower bound of the Posttreatment Week 4 visit were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O11">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O12">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O13">
            <title>Cohort B, Group 7 (12 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
          </group>
          <group group_id="O14">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SVR 4 Weeks After Discontinuation of Therapy (SVR4)</title>
          <description>SVR4 was defined as HCV RNA &lt; LLOQ at 4 weeks after stopping study treatment.</description>
          <population>Full Analysis Set. Participants in Cohort A who received a liver transplant prior to the lower bound of the Posttreatment Week 4 visit were not included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="56"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="26"/>
                <count group_id="O10" value="26"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="88.9"/>
                    <measurement group_id="O3" value="90.9"/>
                    <measurement group_id="O4" value="95.7"/>
                    <measurement group_id="O5" value="96.4"/>
                    <measurement group_id="O6" value="98.2"/>
                    <measurement group_id="O7" value="96.2"/>
                    <measurement group_id="O8" value="100.0"/>
                    <measurement group_id="O9" value="88.5"/>
                    <measurement group_id="O10" value="92.3"/>
                    <measurement group_id="O11" value="100.0"/>
                    <measurement group_id="O12" value="75.0"/>
                    <measurement group_id="O13" value="100.0"/>
                    <measurement group_id="O14" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With SVR 8 Weeks After Discontinuation of Therapy (SVR8)</title>
        <description>SVR8 was defined as HCV RNA &lt; LLOQ at 8 weeks after stopping study treatment.</description>
        <time_frame>Posttreatment Week 8</time_frame>
        <population>Full Analysis Set. Participants in Cohort A who received a liver transplant prior to the lower bound of the Posttreatment Week 8 visit were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O11">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O12">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O13">
            <title>Cohort B, Group 7 (12 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
          </group>
          <group group_id="O14">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SVR 8 Weeks After Discontinuation of Therapy (SVR8)</title>
          <description>SVR8 was defined as HCV RNA &lt; LLOQ at 8 weeks after stopping study treatment.</description>
          <population>Full Analysis Set. Participants in Cohort A who received a liver transplant prior to the lower bound of the Posttreatment Week 8 visit were not included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="56"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="26"/>
                <count group_id="O10" value="26"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7"/>
                    <measurement group_id="O2" value="88.9"/>
                    <measurement group_id="O3" value="86.4"/>
                    <measurement group_id="O4" value="95.7"/>
                    <measurement group_id="O5" value="96.4"/>
                    <measurement group_id="O6" value="98.2"/>
                    <measurement group_id="O7" value="96.2"/>
                    <measurement group_id="O8" value="100.0"/>
                    <measurement group_id="O9" value="88.5"/>
                    <measurement group_id="O10" value="88.5"/>
                    <measurement group_id="O11" value="60.0"/>
                    <measurement group_id="O12" value="75.0"/>
                    <measurement group_id="O13" value="100.0"/>
                    <measurement group_id="O14" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With SVR 24 Weeks After Discontinuation of Therapy (SVR24)</title>
        <description>SVR24 was defined as HCV RNA &lt; LLOQ at 24 weeks after stopping study treatment.</description>
        <time_frame>Posttreatment Week 24</time_frame>
        <population>Full Analysis Set. Participants in Cohort A who received a liver transplant prior to the lower bound of the Posttreatment Week 24 visit were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O11">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O12">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O13">
            <title>Cohort B, Group 7 (12 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
          </group>
          <group group_id="O14">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SVR 24 Weeks After Discontinuation of Therapy (SVR24)</title>
          <description>SVR24 was defined as HCV RNA &lt; LLOQ at 24 weeks after stopping study treatment.</description>
          <population>Full Analysis Set. Participants in Cohort A who received a liver transplant prior to the lower bound of the Posttreatment Week 24 visit were not included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="56"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="26"/>
                <count group_id="O10" value="26"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7"/>
                    <measurement group_id="O2" value="88.9"/>
                    <measurement group_id="O3" value="85.7"/>
                    <measurement group_id="O4" value="87.0"/>
                    <measurement group_id="O5" value="96.4"/>
                    <measurement group_id="O6" value="98.2"/>
                    <measurement group_id="O7" value="96.2"/>
                    <measurement group_id="O8" value="96.0"/>
                    <measurement group_id="O9" value="84.6"/>
                    <measurement group_id="O10" value="88.5"/>
                    <measurement group_id="O11" value="60.0"/>
                    <measurement group_id="O12" value="75.0"/>
                    <measurement group_id="O13" value="100.0"/>
                    <measurement group_id="O14" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologic Failure</title>
        <description>Virologic failure was defined as:
On-treatment virologic failure:
Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ on 2 consecutive measurements while on treatment), or
Rebound (confirmed &gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment)
Virologic relapse:
Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA &lt; LLOQ at last on-treatment visit.</description>
        <time_frame>Up to Posttreatment Week 24</time_frame>
        <population>Full Analysis Set. Participants were excluded from the analysis if they received a liver transplant while on study (with HCV RNA &lt;LLOQ at transplant) prior to lower bound of Posttreatment Week 12 visit window.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O11">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O12">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O13">
            <title>Cohort B, Group 7 (12 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
          </group>
          <group group_id="O14">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Failure</title>
          <description>Virologic failure was defined as:
On-treatment virologic failure:
Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ on 2 consecutive measurements while on treatment), or
Rebound (confirmed &gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment)
Virologic relapse:
Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA &lt; LLOQ at last on-treatment visit.</description>
          <population>Full Analysis Set. Participants were excluded from the analysis if they received a liver transplant while on study (with HCV RNA &lt;LLOQ at transplant) prior to lower bound of Posttreatment Week 12 visit window.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="56"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="26"/>
                <count group_id="O10" value="26"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="3.7"/>
                    <measurement group_id="O3" value="4.5"/>
                    <measurement group_id="O4" value="8.7"/>
                    <measurement group_id="O5" value="3.6"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="3.8"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="40.0"/>
                    <measurement group_id="O12" value="25.0"/>
                    <measurement group_id="O13" value="3.6"/>
                    <measurement group_id="O14" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Posttransplant Virologic Response (pTVR) at Posttransplant Week 12</title>
        <description>pTVR was defined as HCV RNA &lt; LLOQ at Week 12 after transplant.</description>
        <time_frame>Posttransplant Week 12</time_frame>
        <population>Participants who had a liver transplant while on study were analyzed if their last observed HCV RNA measurement prior to transplant was &lt; LLOQ. Participants who received a transplant from an HCV-infected donor were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>All LDV/SOF+RBV</title>
            <description>All participants in the analysis are presented in a single group, regardless of randomization group assignment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Posttransplant Virologic Response (pTVR) at Posttransplant Week 12</title>
          <description>pTVR was defined as HCV RNA &lt; LLOQ at Week 12 after transplant.</description>
          <population>Participants who had a liver transplant while on study were analyzed if their last observed HCV RNA measurement prior to transplant was &lt; LLOQ. Participants who received a transplant from an HCV-infected donor were excluded from analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HCV RNA &lt; LLOQ at Week 1</title>
        <time_frame>Week 1</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O11">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O12">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O13">
            <title>Cohort B, Group 7 (12 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
          </group>
          <group group_id="O14">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HCV RNA &lt; LLOQ at Week 1</title>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="56"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="26"/>
                <count group_id="O10" value="26"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="6.9"/>
                    <measurement group_id="O3" value="13.0"/>
                    <measurement group_id="O4" value="3.8"/>
                    <measurement group_id="O5" value="16.4"/>
                    <measurement group_id="O6" value="12.5"/>
                    <measurement group_id="O7" value="15.4"/>
                    <measurement group_id="O8" value="4.0"/>
                    <measurement group_id="O9" value="3.8"/>
                    <measurement group_id="O10" value="7.7"/>
                    <measurement group_id="O11" value="0.0"/>
                    <measurement group_id="O12" value="0.0"/>
                    <measurement group_id="O13" value="25.0"/>
                    <measurement group_id="O14" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HCV RNA &lt; LLOQ at Week 2</title>
        <time_frame>Week 2</time_frame>
        <population>Participants in the Full Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O11">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O12">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O13">
            <title>Cohort B, Group 7 (12 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
          </group>
          <group group_id="O14">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HCV RNA &lt; LLOQ at Week 2</title>
          <population>Participants in the Full Analysis Set with available data were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="25"/>
                <count group_id="O10" value="26"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7"/>
                    <measurement group_id="O2" value="41.4"/>
                    <measurement group_id="O3" value="39.1"/>
                    <measurement group_id="O4" value="38.5"/>
                    <measurement group_id="O5" value="49.1"/>
                    <measurement group_id="O6" value="41.8"/>
                    <measurement group_id="O7" value="34.6"/>
                    <measurement group_id="O8" value="28.0"/>
                    <measurement group_id="O9" value="8.0"/>
                    <measurement group_id="O10" value="42.3"/>
                    <measurement group_id="O11" value="40.0"/>
                    <measurement group_id="O12" value="25.0"/>
                    <measurement group_id="O13" value="50.0"/>
                    <measurement group_id="O14" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HCV RNA &lt; LLOQ at Week 4</title>
        <time_frame>Week 4</time_frame>
        <population>Participants in the Full Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O11">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O12">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O13">
            <title>Cohort B, Group 7 (12 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
          </group>
          <group group_id="O14">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HCV RNA &lt; LLOQ at Week 4</title>
          <population>Participants in the Full Analysis Set with available data were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="25"/>
                <count group_id="O10" value="26"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="82.8"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="84.6"/>
                    <measurement group_id="O5" value="87.3"/>
                    <measurement group_id="O6" value="90.9"/>
                    <measurement group_id="O7" value="88.5"/>
                    <measurement group_id="O8" value="80.0"/>
                    <measurement group_id="O9" value="72.0"/>
                    <measurement group_id="O10" value="88.5"/>
                    <measurement group_id="O11" value="100.0"/>
                    <measurement group_id="O12" value="100.0"/>
                    <measurement group_id="O13" value="100.0"/>
                    <measurement group_id="O14" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HCV RNA &lt; LLOQ at Week 6</title>
        <time_frame>Week 6</time_frame>
        <population>Participants in the Full Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O11">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O12">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O13">
            <title>Cohort B, Group 7 (12 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
          </group>
          <group group_id="O14">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HCV RNA &lt; LLOQ at Week 6</title>
          <population>Participants in the Full Analysis Set with available data were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="25"/>
                <count group_id="O10" value="26"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="96.2"/>
                    <measurement group_id="O5" value="96.4"/>
                    <measurement group_id="O6" value="100.0"/>
                    <measurement group_id="O7" value="100.0"/>
                    <measurement group_id="O8" value="100.0"/>
                    <measurement group_id="O9" value="100.0"/>
                    <measurement group_id="O10" value="100.0"/>
                    <measurement group_id="O11" value="100.0"/>
                    <measurement group_id="O12" value="100.0"/>
                    <measurement group_id="O13" value="100.0"/>
                    <measurement group_id="O14" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HCV RNA &lt; LLOQ at Week 8</title>
        <time_frame>Week 8</time_frame>
        <population>Participants in the Full Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O11">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O12">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O13">
            <title>Cohort B, Group 7 (12 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
          </group>
          <group group_id="O14">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HCV RNA &lt; LLOQ at Week 8</title>
          <population>Participants in the Full Analysis Set with available data were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="25"/>
                <count group_id="O10" value="26"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="96.6"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="92.0"/>
                    <measurement group_id="O5" value="100.0"/>
                    <measurement group_id="O6" value="100.0"/>
                    <measurement group_id="O7" value="100.0"/>
                    <measurement group_id="O8" value="100.0"/>
                    <measurement group_id="O9" value="96.0"/>
                    <measurement group_id="O10" value="96.2"/>
                    <measurement group_id="O11" value="100.0"/>
                    <measurement group_id="O12" value="100.0"/>
                    <measurement group_id="O13" value="100.0"/>
                    <measurement group_id="O14" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HCV RNA &lt; LLOQ at Week 12</title>
        <time_frame>Week 12</time_frame>
        <population>Participants in the Full Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O11">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O12">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O13">
            <title>Cohort B, Group 7 (12 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
          </group>
          <group group_id="O14">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HCV RNA &lt; LLOQ at Week 12</title>
          <population>Participants in the Full Analysis Set with available data were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="23"/>
                <count group_id="O10" value="25"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="100.0"/>
                    <measurement group_id="O6" value="100.0"/>
                    <measurement group_id="O7" value="96.0"/>
                    <measurement group_id="O8" value="100.0"/>
                    <measurement group_id="O9" value="100.0"/>
                    <measurement group_id="O10" value="100.0"/>
                    <measurement group_id="O11" value="100.0"/>
                    <measurement group_id="O12" value="100.0"/>
                    <measurement group_id="O13" value="100.0"/>
                    <measurement group_id="O14" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HCV RNA &lt; LLOQ at Week 16</title>
        <time_frame>Week 16</time_frame>
        <population>Participants in the Full Analysis Set who were randomized to a 24-week treatment group and had available data were analyzed. 12-week treatment groups (did not collect data past Week 12) are not presented in this table.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O3">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O4">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HCV RNA &lt; LLOQ at Week 16</title>
          <population>Participants in the Full Analysis Set who were randomized to a 24-week treatment group and had available data were analyzed. 12-week treatment groups (did not collect data past Week 12) are not presented in this table.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="100.0"/>
                    <measurement group_id="O6" value="100.0"/>
                    <measurement group_id="O7" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HCV RNA &lt; LLOQ at Week 20</title>
        <time_frame>Week 20</time_frame>
        <population>Participants in the Full Analysis Set who were randomized to a 24-week treatment group and had available data were analyzed. 12-week treatment groups (did not collect data past Week 12) are not presented in this table.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O3">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O4">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HCV RNA &lt; LLOQ at Week 20</title>
          <population>Participants in the Full Analysis Set who were randomized to a 24-week treatment group and had available data were analyzed. 12-week treatment groups (did not collect data past Week 12) are not presented in this table.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="100.0"/>
                    <measurement group_id="O6" value="100.0"/>
                    <measurement group_id="O7" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HCV RNA &lt; LLOQ at Week 24</title>
        <time_frame>Week 24</time_frame>
        <population>Participants in the Full Analysis Set who were randomized to a 24-week treatment group and had available data were analyzed. 12-week treatment groups (did not collect data past Week 12) are not presented in this table.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O3">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O4">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HCV RNA &lt; LLOQ at Week 24</title>
          <population>Participants in the Full Analysis Set who were randomized to a 24-week treatment group and had available data were analyzed. 12-week treatment groups (did not collect data past Week 12) are not presented in this table.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="100.0"/>
                    <measurement group_id="O6" value="100.0"/>
                    <measurement group_id="O7" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HCV RNA and Change From Baseline at Week 1</title>
        <time_frame>Baseline; Week 1</time_frame>
        <population>Participants in the Full Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O11">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O12">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O13">
            <title>Cohort B, Group 7 (12 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
          </group>
          <group group_id="O14">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>HCV RNA and Change From Baseline at Week 1</title>
          <population>Participants in the Full Analysis Set with available data were analyzed.</population>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="25"/>
                <count group_id="O10" value="26"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" spread="0.695"/>
                    <measurement group_id="O2" value="2.49" spread="0.830"/>
                    <measurement group_id="O3" value="2.11" spread="0.643"/>
                    <measurement group_id="O4" value="2.46" spread="0.968"/>
                    <measurement group_id="O5" value="2.33" spread="0.983"/>
                    <measurement group_id="O6" value="2.42" spread="0.730"/>
                    <measurement group_id="O7" value="2.40" spread="0.890"/>
                    <measurement group_id="O8" value="2.86" spread="0.792"/>
                    <measurement group_id="O9" value="2.84" spread="0.678"/>
                    <measurement group_id="O10" value="2.56" spread="0.774"/>
                    <measurement group_id="O11" value="2.76" spread="0.571"/>
                    <measurement group_id="O12" value="2.75" spread="1.065"/>
                    <measurement group_id="O13" value="2.28" spread="1.149"/>
                    <measurement group_id="O14" value="4.30" spread="1.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.59" spread="0.476"/>
                    <measurement group_id="O2" value="-3.34" spread="0.658"/>
                    <measurement group_id="O3" value="-3.47" spread="0.579"/>
                    <measurement group_id="O4" value="-3.32" spread="0.669"/>
                    <measurement group_id="O5" value="-4.14" spread="0.721"/>
                    <measurement group_id="O6" value="-3.98" spread="0.682"/>
                    <measurement group_id="O7" value="-3.80" spread="0.712"/>
                    <measurement group_id="O8" value="-3.86" spread="0.759"/>
                    <measurement group_id="O9" value="-3.41" spread="0.409"/>
                    <measurement group_id="O10" value="-3.68" spread="0.506"/>
                    <measurement group_id="O11" value="-3.75" spread="0.584"/>
                    <measurement group_id="O12" value="-3.52" spread="1.028"/>
                    <measurement group_id="O13" value="-4.22" spread="0.864"/>
                    <measurement group_id="O14" value="-2.76" spread="0.526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HCV RNA and Change From Baseline at Week 2</title>
        <time_frame>Baseline; Week 2</time_frame>
        <population>Participants in the Full Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O11">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O12">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O13">
            <title>Cohort B, Group 7 (12 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
          </group>
          <group group_id="O14">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>HCV RNA and Change From Baseline at Week 2</title>
          <population>Participants in the Full Analysis Set with available data were analyzed.</population>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="52"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="25"/>
                <count group_id="O10" value="26"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="0.484"/>
                    <measurement group_id="O2" value="1.67" spread="0.574"/>
                    <measurement group_id="O3" value="1.49" spread="0.404"/>
                    <measurement group_id="O4" value="1.82" spread="0.748"/>
                    <measurement group_id="O5" value="1.64" spread="0.751"/>
                    <measurement group_id="O6" value="1.59" spread="0.516"/>
                    <measurement group_id="O7" value="1.73" spread="0.631"/>
                    <measurement group_id="O8" value="1.91" spread="0.641"/>
                    <measurement group_id="O9" value="2.03" spread="0.585"/>
                    <measurement group_id="O10" value="1.76" spread="0.628"/>
                    <measurement group_id="O11" value="1.80" spread="0.645"/>
                    <measurement group_id="O12" value="2.00" spread="0.746"/>
                    <measurement group_id="O13" value="1.66" spread="0.637"/>
                    <measurement group_id="O14" value="1.61">1 participant analyzed: SD not calculable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.25" spread="0.575"/>
                    <measurement group_id="O2" value="-4.16" spread="0.748"/>
                    <measurement group_id="O3" value="-4.09" spread="0.604"/>
                    <measurement group_id="O4" value="-3.98" spread="0.581"/>
                    <measurement group_id="O5" value="-4.83" spread="0.720"/>
                    <measurement group_id="O6" value="-4.79" spread="0.845"/>
                    <measurement group_id="O7" value="-4.48" spread="0.668"/>
                    <measurement group_id="O8" value="-4.84" spread="0.636"/>
                    <measurement group_id="O9" value="-4.22" spread="0.489"/>
                    <measurement group_id="O10" value="-4.47" spread="0.503"/>
                    <measurement group_id="O11" value="-4.56" spread="0.765"/>
                    <measurement group_id="O12" value="-4.26" spread="0.825"/>
                    <measurement group_id="O13" value="-4.85" spread="1.090"/>
                    <measurement group_id="O14" value="-4.81">1 participant analyzed: standard deviation (SD) not calculable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HCV RNA and Change From Baseline at Week 4</title>
        <time_frame>Baseline; Week 4</time_frame>
        <population>Participants in the Full Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O11">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O12">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O13">
            <title>Cohort B, Group 7 (12 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
          </group>
          <group group_id="O14">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>HCV RNA and Change From Baseline at Week 4</title>
          <population>Participants in the Full Analysis Set with available data were analyzed.</population>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="25"/>
                <count group_id="O10" value="26"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="0.117"/>
                    <measurement group_id="O2" value="1.21" spread="0.153"/>
                    <measurement group_id="O3" value="1.15" spread="0.000"/>
                    <measurement group_id="O4" value="1.23" spread="0.265"/>
                    <measurement group_id="O5" value="1.24" spread="0.271"/>
                    <measurement group_id="O6" value="1.16" spread="0.065"/>
                    <measurement group_id="O7" value="1.18" spread="0.120"/>
                    <measurement group_id="O8" value="1.23" spread="0.212"/>
                    <measurement group_id="O9" value="1.24" spread="0.184"/>
                    <measurement group_id="O10" value="1.18" spread="0.150"/>
                    <measurement group_id="O11" value="1.15" spread="0.000"/>
                    <measurement group_id="O12" value="1.15" spread="0.000"/>
                    <measurement group_id="O13" value="1.15" spread="0.000"/>
                    <measurement group_id="O14" value="1.67" spread="0.738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.65" spread="0.668"/>
                    <measurement group_id="O2" value="-4.63" spread="0.789"/>
                    <measurement group_id="O3" value="-4.44" spread="0.618"/>
                    <measurement group_id="O4" value="-4.56" spread="0.655"/>
                    <measurement group_id="O5" value="-5.23" spread="0.629"/>
                    <measurement group_id="O6" value="-5.24" spread="0.929"/>
                    <measurement group_id="O7" value="-5.01" spread="0.736"/>
                    <measurement group_id="O8" value="-5.52" spread="0.376"/>
                    <measurement group_id="O9" value="-5.01" spread="0.537"/>
                    <measurement group_id="O10" value="-5.05" spread="0.662"/>
                    <measurement group_id="O11" value="-5.21" spread="0.422"/>
                    <measurement group_id="O12" value="-5.12" spread="0.368"/>
                    <measurement group_id="O13" value="-5.36" spread="1.237"/>
                    <measurement group_id="O14" value="-5.39" spread="0.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HCV RNA and Change From Baseline at Week 6</title>
        <time_frame>Baseline; Week 6</time_frame>
        <population>Participants in the Full Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O11">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O12">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O13">
            <title>Cohort B, Group 7 (12 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
          </group>
          <group group_id="O14">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>HCV RNA and Change From Baseline at Week 6</title>
          <population>Participants in the Full Analysis Set with available data were analyzed.</population>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="25"/>
                <count group_id="O10" value="26"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.000"/>
                    <measurement group_id="O2" value="1.15" spread="0.000"/>
                    <measurement group_id="O3" value="1.15" spread="0.000"/>
                    <measurement group_id="O4" value="1.15" spread="0.042"/>
                    <measurement group_id="O5" value="1.15" spread="0.004"/>
                    <measurement group_id="O6" value="1.15" spread="0.000"/>
                    <measurement group_id="O7" value="1.15" spread="0.000"/>
                    <measurement group_id="O8" value="1.15" spread="0.000"/>
                    <measurement group_id="O9" value="1.15" spread="0.000"/>
                    <measurement group_id="O10" value="1.15" spread="0.000"/>
                    <measurement group_id="O11" value="1.15" spread="0.000"/>
                    <measurement group_id="O12" value="1.15" spread="0.000"/>
                    <measurement group_id="O13" value="1.15" spread="0.000"/>
                    <measurement group_id="O14" value="1.15">1 participant analyzed: SD not calculable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.70" spread="0.676"/>
                    <measurement group_id="O2" value="-4.69" spread="0.822"/>
                    <measurement group_id="O3" value="-4.47" spread="0.616"/>
                    <measurement group_id="O4" value="-4.61" spread="0.695"/>
                    <measurement group_id="O5" value="-5.32" spread="0.618"/>
                    <measurement group_id="O6" value="-5.25" spread="0.936"/>
                    <measurement group_id="O7" value="-5.05" spread="0.788"/>
                    <measurement group_id="O8" value="-5.60" spread="0.345"/>
                    <measurement group_id="O9" value="-5.10" spread="0.559"/>
                    <measurement group_id="O10" value="-5.09" spread="0.669"/>
                    <measurement group_id="O11" value="-5.21" spread="0.422"/>
                    <measurement group_id="O12" value="-5.12" spread="0.368"/>
                    <measurement group_id="O13" value="-5.36" spread="1.237"/>
                    <measurement group_id="O14" value="-5.28">1 participant analyzed: SD not calculable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HCV RNA and Change From Baseline at Week 8</title>
        <time_frame>Baseline; Week 8</time_frame>
        <population>Participants in the Full Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O11">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O12">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O13">
            <title>Cohort B, Group 7 (12 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
          </group>
          <group group_id="O14">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>HCV RNA and Change From Baseline at Week 8</title>
          <population>Participants in the Full Analysis Set with available data were analyzed.</population>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="24"/>
                <count group_id="O10" value="25"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.000"/>
                    <measurement group_id="O2" value="1.15" spread="0.000"/>
                    <measurement group_id="O3" value="1.15" spread="0.000"/>
                    <measurement group_id="O4" value="1.16" spread="0.081"/>
                    <measurement group_id="O5" value="1.15" spread="0.000"/>
                    <measurement group_id="O6" value="1.15" spread="0.000"/>
                    <measurement group_id="O7" value="1.15" spread="0.000"/>
                    <measurement group_id="O8" value="1.15" spread="0.000"/>
                    <measurement group_id="O9" value="1.15" spread="0.000"/>
                    <measurement group_id="O10" value="1.15" spread="0.000"/>
                    <measurement group_id="O11" value="1.15" spread="0.000"/>
                    <measurement group_id="O12" value="1.15" spread="0.000"/>
                    <measurement group_id="O13" value="1.15" spread="0.000"/>
                    <measurement group_id="O14" value="1.22" spread="0.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.70" spread="0.676"/>
                    <measurement group_id="O2" value="-4.67" spread="0.834"/>
                    <measurement group_id="O3" value="-4.47" spread="0.616"/>
                    <measurement group_id="O4" value="-4.61" spread="0.715"/>
                    <measurement group_id="O5" value="-5.33" spread="0.615"/>
                    <measurement group_id="O6" value="-5.25" spread="0.936"/>
                    <measurement group_id="O7" value="-5.05" spread="0.788"/>
                    <measurement group_id="O8" value="-5.60" spread="0.345"/>
                    <measurement group_id="O9" value="-5.11" spread="0.571"/>
                    <measurement group_id="O10" value="-5.10" spread="0.682"/>
                    <measurement group_id="O11" value="-5.21" spread="0.422"/>
                    <measurement group_id="O12" value="-5.12" spread="0.368"/>
                    <measurement group_id="O13" value="-5.36" spread="1.237"/>
                    <measurement group_id="O14" value="-5.83" spread="0.787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HCV RNA and Change From Baseline at Week 12</title>
        <time_frame>Baseline; Week 12</time_frame>
        <population>Participants in the Full Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O11">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O12">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O13">
            <title>Cohort B, Group 7 (12 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
          </group>
          <group group_id="O14">
            <title>Cohort B, Group 7 (24 wk): FCH</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
          </group>
        </group_list>
        <measure>
          <title>HCV RNA and Change From Baseline at Week 12</title>
          <population>Participants in the Full Analysis Set with available data were analyzed.</population>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="23"/>
                <count group_id="O10" value="25"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.000"/>
                    <measurement group_id="O2" value="1.15" spread="0.000"/>
                    <measurement group_id="O3" value="1.15" spread="0.000"/>
                    <measurement group_id="O4" value="1.15" spread="0.000"/>
                    <measurement group_id="O5" value="1.15" spread="0.000"/>
                    <measurement group_id="O6" value="1.15" spread="0.000"/>
                    <measurement group_id="O7" value="1.15" spread="0.000"/>
                    <measurement group_id="O8" value="1.15" spread="0.000"/>
                    <measurement group_id="O9" value="1.15" spread="0.000"/>
                    <measurement group_id="O10" value="1.15" spread="0.000"/>
                    <measurement group_id="O11" value="1.15" spread="0.000"/>
                    <measurement group_id="O12" value="1.15" spread="0.000"/>
                    <measurement group_id="O13" value="1.15" spread="0.000"/>
                    <measurement group_id="O14" value="1.15" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.70" spread="0.676"/>
                    <measurement group_id="O2" value="-4.70" spread="0.842"/>
                    <measurement group_id="O3" value="-4.44" spread="0.614"/>
                    <measurement group_id="O4" value="-4.62" spread="0.737"/>
                    <measurement group_id="O5" value="-5.33" spread="0.615"/>
                    <measurement group_id="O6" value="-5.25" spread="0.943"/>
                    <measurement group_id="O7" value="-5.09" spread="0.781"/>
                    <measurement group_id="O8" value="-5.60" spread="0.345"/>
                    <measurement group_id="O9" value="-5.14" spread="0.562"/>
                    <measurement group_id="O10" value="-5.10" spread="0.682"/>
                    <measurement group_id="O11" value="-5.21" spread="0.422"/>
                    <measurement group_id="O12" value="-5.12" spread="0.368"/>
                    <measurement group_id="O13" value="-5.36" spread="1.237"/>
                    <measurement group_id="O14" value="-5.91" spread="0.897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Decrease, No Change, or Increase Between Baseline and Posttreatment Week 4 in MELD Score</title>
        <description>Model for End-Stage Liver Disease (MELD) scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40; higher scores/increased scores indicate greater severity of disease.</description>
        <time_frame>Baseline to Posttreatment Week 4</time_frame>
        <population>Full Analysis Set. Participants with cirrhosis were analyzed if they had measurements at both baseline and Posttreatment Week 4. Only groups with cirrhotic participants are presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O3">
            <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O4">
            <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O5">
            <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O6">
            <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
          </group>
          <group group_id="O7">
            <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O8">
            <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
          </group>
          <group group_id="O9">
            <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
          <group group_id="O10">
            <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease, No Change, or Increase Between Baseline and Posttreatment Week 4 in MELD Score</title>
          <description>Model for End-Stage Liver Disease (MELD) scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40; higher scores/increased scores indicate greater severity of disease.</description>
          <population>Full Analysis Set. Participants with cirrhosis were analyzed if they had measurements at both baseline and Posttreatment Week 4. Only groups with cirrhotic participants are presented.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="21"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7"/>
                    <measurement group_id="O2" value="68.0"/>
                    <measurement group_id="O3" value="61.9"/>
                    <measurement group_id="O4" value="80.0"/>
                    <measurement group_id="O5" value="30.4"/>
                    <measurement group_id="O6" value="52.0"/>
                    <measurement group_id="O7" value="66.7"/>
                    <measurement group_id="O8" value="70.0"/>
                    <measurement group_id="O9" value="40.0"/>
                    <measurement group_id="O10" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="9.5"/>
                    <measurement group_id="O4" value="15.0"/>
                    <measurement group_id="O5" value="39.1"/>
                    <measurement group_id="O6" value="16.0"/>
                    <measurement group_id="O7" value="19.0"/>
                    <measurement group_id="O8" value="5.0"/>
                    <measurement group_id="O9" value="20.0"/>
                    <measurement group_id="O10" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4"/>
                    <measurement group_id="O2" value="12.0"/>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="5.0"/>
                    <measurement group_id="O5" value="30.4"/>
                    <measurement group_id="O6" value="32.0"/>
                    <measurement group_id="O7" value="14.3"/>
                    <measurement group_id="O8" value="25.0"/>
                    <measurement group_id="O9" value="40.0"/>
                    <measurement group_id="O10" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Decrease, No Change, or Increase Between Baseline and Posttreatment Week 4 in CPT Score</title>
        <description>CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15 (maximum score for entry into the study was 12); higher scores/increased scores indicate greater severity of disease. Groups are arranged by cohort, then by duration of treatment, then by CPT class at baseline.</description>
        <time_frame>Baseline to Posttreatment Week 4</time_frame>
        <population>Full Analysis Set. Cirrhotic participants were analyzed if they had measurements at both baseline and Posttreatment Week 4. Only groups with cirrhotic participants are presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A: Baseline CPT Class A (24 wk)</title>
            <description>Includes participants in Cohort A (24 wk) with CPT score A at baseline (randomization was based on screening measurement), and who had CPT score assessments at both baseline and Posttreatment Week 4.</description>
          </group>
          <group group_id="O2">
            <title>Cohort A: Baseline CPT Class B (12 wk)</title>
            <description>Includes participants in Cohort A (12 wk) with CPT score B at baseline (randomization was based on screening measurement), and who had CPT score assessments at both baseline and Posttreatment Week 4.</description>
          </group>
          <group group_id="O3">
            <title>Cohort A: Baseline CPT Class B (24 wk)</title>
            <description>Includes participants in Cohort A (24 wk) with CPT score B at baseline (randomization was based on screening measurement), and who had CPT score assessments at both baseline and Posttreatment Week 4.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A: Baseline CPT Class C (12 wk)</title>
            <description>Includes participants in Cohort A (12 wk) with CPT score C at baseline (randomization was based on screening measurement), and who had CPT score assessments at both baseline and Posttreatment Week 4.</description>
          </group>
          <group group_id="O5">
            <title>Cohort A: Baseline CPT Class C (24 wk)</title>
            <description>Includes participants in Cohort A (24 wk) with CPT score C at baseline (randomization was based on screening measurement), and who had CPT score assessments at both baseline and Posttreatment Week 4.</description>
          </group>
          <group group_id="O6">
            <title>Cohort B: Baseline CPT Class A (12 wk)</title>
            <description>Includes participants in Cohort B (12 wk) with CPT score A at baseline (randomization was based on screening measurement), and who had CPT score assessments at both baseline and Posttreatment Week 4.</description>
          </group>
          <group group_id="O7">
            <title>Cohort B: Baseline CPT Class A (24 wk)</title>
            <description>Includes participants in Cohort B (24 wk) with CPT score A at baseline (randomization was based on screening measurement), and who had CPT score assessments at both baseline and Posttreatment Week 4.</description>
          </group>
          <group group_id="O8">
            <title>Cohort B: Baseline CPT Class B (12 wk)</title>
            <description>Includes participants in Cohort B (12 wk) with CPT score B at baseline (randomization was based on screening measurement), and who had CPT score assessments at both baseline and Posttreatment Week 4.</description>
          </group>
          <group group_id="O9">
            <title>Cohort B: Baseline CPT Class B (24 wk)</title>
            <description>Includes participants in Cohort B (24 wk) with CPT score B at baseline (randomization was based on screening measurement), and who had CPT score assessments at both baseline and Posttreatment Week 4.</description>
          </group>
          <group group_id="O10">
            <title>Cohort B: Baseline CPT Class C (12 wk)</title>
            <description>Includes participants in Cohort B (12 wk) with CPT score C at baseline (randomization was based on screening measurement), and who had CPT score assessments at both baseline and Posttreatment Week 4.</description>
          </group>
          <group group_id="O11">
            <title>Cohort B: Baseline CPT Class C (24 wk)</title>
            <description>Includes participants in Cohort B (24 wk) with CPT score C at baseline (randomization was based on screening measurement), and who had CPT score assessments at both baseline and Posttreatment Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease, No Change, or Increase Between Baseline and Posttreatment Week 4 in CPT Score</title>
          <description>CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15 (maximum score for entry into the study was 12); higher scores/increased scores indicate greater severity of disease. Groups are arranged by cohort, then by duration of treatment, then by CPT class at baseline.</description>
          <population>Full Analysis Set. Cirrhotic participants were analyzed if they had measurements at both baseline and Posttreatment Week 4. Only groups with cirrhotic participants are presented.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="23"/>
                <count group_id="O9" value="22"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="63.3"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="89.5"/>
                    <measurement group_id="O5" value="72.2"/>
                    <measurement group_id="O6" value="18.2"/>
                    <measurement group_id="O7" value="47.8"/>
                    <measurement group_id="O8" value="56.5"/>
                    <measurement group_id="O9" value="59.1"/>
                    <measurement group_id="O10" value="50.0"/>
                    <measurement group_id="O11" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="23.3"/>
                    <measurement group_id="O3" value="38.5"/>
                    <measurement group_id="O4" value="10.5"/>
                    <measurement group_id="O5" value="27.8"/>
                    <measurement group_id="O6" value="68.2"/>
                    <measurement group_id="O7" value="52.2"/>
                    <measurement group_id="O8" value="34.8"/>
                    <measurement group_id="O9" value="31.8"/>
                    <measurement group_id="O10" value="50.0"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="13.3"/>
                    <measurement group_id="O3" value="11.5"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="13.6"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="8.7"/>
                    <measurement group_id="O9" value="9.1"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 24 weeks on treatment plus 30 days</time_frame>
      <desc>Safety Analysis Set: participants who were enrolled and received at least one dose of study drug</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort A, Group 1 (12 wk): CPT Class B (7-9)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
        </group>
        <group group_id="E2">
          <title>Cohort A, Group 1 (24 wk): CPT Class B (7-9)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
        </group>
        <group group_id="E3">
          <title>Cohort A, Group 2 (12 wk): CPT Class C (10-12)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
        </group>
        <group group_id="E4">
          <title>Cohort A, Group 2 (24 wk): CPT Class C (10-12)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
        </group>
        <group group_id="E5">
          <title>Cohort B, Group 3 (12 wk): F0-F3 Fibrosis</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3</description>
        </group>
        <group group_id="E6">
          <title>Cohort B, Group 3 (24 wk): F0-F3 Fibrosis</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3</description>
        </group>
        <group group_id="E7">
          <title>Cohort B, Group 4 (12 wk): CPT Class A (5-6)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)</description>
        </group>
        <group group_id="E8">
          <title>Cohort B, Group 4 (24 wk): CPT Class A (5-6)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)</description>
        </group>
        <group group_id="E9">
          <title>Cohort B, Group 5 (12 wk): CPT Class B (7-9)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)</description>
        </group>
        <group group_id="E10">
          <title>Cohort B, Group 5 (24 wk): CPT Class B (7-9)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)</description>
        </group>
        <group group_id="E11">
          <title>Cohort B, Group 6 (12 wk): CPT Class C (10-12)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)</description>
        </group>
        <group group_id="E12">
          <title>Cohort B, Group 6 (24 wk): CPT Class C (10-12)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (divided daily dose starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)</description>
        </group>
        <group group_id="E13">
          <title>Cohort B, Group 7 (12 wk): FCH</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with fibrosing cholestatic hepatitis (FCH)</description>
        </group>
        <group group_id="E14">
          <title>Cohort B, Group 7 (24 wk): FCH</title>
          <description>LDV/SOF (90/400 mg) FDC tablet once daily plus RBV tablets (weight-based divided daily dose: &lt; 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Splenic vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastric varices</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastric varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oesophageal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hepatic artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Clostridium difficile sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fungal peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pharyngeal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Progressive multifocal leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Complications of transplanted liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Graft loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Post transplant lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hepatic hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="54" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="54" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="23" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="23" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="26" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="31" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pseudocyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Peritoneal tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Affect lability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Scrotal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Increased upper airway secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no limitations affecting the analysis or results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosures</name_or_title>
      <organization>Gilead Sciences</organization>
      <email>ClinicalTrialDisclosures@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

